Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 30.8.2005 | EN | Official Journal of the European Union | L 224/7 |

---

COMMISSION DECISION

of 23 August 2005

on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council

(notified under document number C(2005) 333)

(Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)

(Text with EEA relevance)

(2005/626/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer [(1)](#ntr1-L_2005224EN.01000701-E0001), and in particular Article 3(1) thereof,

Whereas:

|  |  |
| --- | --- |
| (1) | The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane. |

|  |  |
| --- | --- |
| (2) | Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them. |

|  |  |
| --- | --- |
| (3) | Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party. |

|  |  |
| --- | --- |
| (4) | Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol. |

|  |  |
| --- | --- |
| (5) | Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Norway, Portugal, The Netherlands, Slovak Republic, Slovenia, Spain, Sweden and the United Kingdom have notified the United Nations Environment Programme [(2)](#ntr2-L_2005224EN.01000701-E0002) that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of CFC-MDIs that contain active ingredients belonging to the therapeutic categories of ‘short-acting beta agonist bronchiodilators’, ‘inhaled steroids’ and ‘anticholinergic bronchiodilators’. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1). |

|  |  |
| --- | --- |
| (6) | The Commission has published a Notice [(3)](#ntr3-L_2005224EN.01000701-E0003) on the 22 July 2004 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2005 and has received declarations on intended essential uses of controlled substances in 2005. |

|  |  |
| --- | --- |
| (7) | For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2005. |

|  |  |
| --- | --- |
| (8) | The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000, |

HAS ADOPTED THIS DECISION:

Article 1

1.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2005 shall be 1 029 770,00 ODP [(4)](#ntr4-L_2005224EN.01000701-E0004) kilograms.

2.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2005 shall be 63 081,71 ODP kilograms.

3.   The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2005 shall be 70,705 ODP kilograms.

4.   The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 145 240,293 ODP kilograms.

5.   The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2005 shall be 815,30 ODP kilograms.

6.   The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 3,04 ODP kilograms.

7.   The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 12,048 ODP kilograms.

Article 2

The chlorofluorocarbon metered-dose inhalers (CFC-MDIs) listed in Annex I shall not be placed on markets that have determined CFCs for these products to be non-essential.

Article 3

During the period 1 January to 31 December 2005 the following rules shall apply:

|  |  |
| --- | --- |
| 1. | The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II. |

|  |  |
| --- | --- |
| 2. | The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III. |

|  |  |
| --- | --- |
| 3. | The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV. |

|  |  |
| --- | --- |
| 4. | The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V. |

|  |  |
| --- | --- |
| 5. | The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI. |

|  |  |
| --- | --- |
| 6. | The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII. |

|  |  |
| --- | --- |
| 7. | The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII. |

|  |  |
| --- | --- |
| 8. | The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX. |

Article 4

This Decision is addressed to the following undertakings:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | 3M Health Care Ltd | | 3M House Morley Street | | Loughborough | | Leicestershire LE11 1EP | | United Kingdom | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Aventis | | London Road, Holmes Chapel | | Cheshire CW4 8BE | | United Kingdom | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Bespak PLC | | North Lynn Industrial Estate | | King's Lynn | | PE30 2JJ — Norfolk | | United Kingdom | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Boehringer Ingelheim GmbH | | Binger Straße 173 | | D-55216 Ingelheim am Rhein | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Chiesi Farmaceutici SpA | | Via Palermo 26/A | | I-43100 Parma | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | GlaxoSmithKline | | Speke Boulevard | | Speke | | L24 9JD — Liverpool | | United Kingdom | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | IG Sprühtechnik GmbH | | Im Hemmet 1 | | D-79664 Wehr | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Inyx Pharmaceuticals Ltd | | Astmoor Industrial Estate | | 9 Arkwright Road RUNCORN | | Cheshire WA7 1NU | | United Kingdom | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | GlaxoSmithKline Pharmaceuticals SA | | Siedziba w Poznaniu | | ul. Grunwaldzka 189 | | 60-322 Poznań | | Poland | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | IVAX Ltd | | Unit 301 Industrial Park | | Waterford | | Ireland | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Laboratorio Aldo Union SA | | Baronesa de Maldá, 73 | | Espluges de Llobregat | | E-08950 Barcelona | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | SICOR S.p.A | | Via Terrazzano 77 | | I-20017 Rho (MI) | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Valeas SpA Pharmaceuticals | | Via Vallisneri, 10 | | I-20133 Milano | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Valois SA | | 50, avenue de l'Europe | | F-78160 Marly Le Roi | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Valvole Aerosol Research Italiana (VARI) | | Spa — LINDAL Group Italia | | Via del Pino, 10 | | Olginate (LC) | | I-23854 | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Acros Organics bvba | | Janssen Pharmaceuticalaan 3a | | B-2440 Geel | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Agfa-Gevaert NV | | Septestraat 27 | | B-2640 Mortsel | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Bie & Berntsen | | Sandbækvej 7 | | DK-2610 Rødovre | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Biosolove BV | | Waalreseweg 17 | | 5554 HA Valkenswaard | | Nederland | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Carl Roth GmbH | | Schoemperlenstraße 3—5 | | D-76185 Karlsruhe | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Elcom Group | | Okružní 988 | | CZ-735 14 Orlová-Lutyně | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Health Protection Inspectorate-Laboratories | | Paldiski mnt 81 | | EE-10617 Tallinn | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Honeywell Specialty Chemicals | | Wunstorfer Straße 40 | | Postfach 100262 | | D-30918 Seelze | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Ineos Fluor Ltd | | PO Box 13, The Heath | | Runcorn Cheshire WA7 4QF | | United Kingdom | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Institut scientifique de service public (ISSeP) | | Rue du Chéra, 200 | | B-4000 Liège | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Katholieke Universiteit Leuven | | Krakenstraat 3 | | B-3000 Leuven | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | LGC Promochem GmbH | | Mercatorstraße 51 | | D-46485 Wesel | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Mallinckrodt Baker BV | | Teugseweg 20 | | 7418 AM Deventer | | Nederland | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Merck KGaA | | Frankfurter Straße 250 | | D-64293 Darmstadt | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Mikro+Polo d.o.o. | | Zagrebška cesta 22 | | SI-2000 Maribor | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Ministry of Defense | | Directorate Material RNLNavy | | PO Box 2070 | | 2500 ES The Hague | | Nederland | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Panreac Quimica SA | | Riera de Sant Cugat, 1 | | E-08110 Montcada I Reixac (Barcelona) | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Rohs Chemie GmbH | | Berliner Str. 54 | | D-53819 Neunkirchen-Seelscheid | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Sanolabor d.d. | | Leskovškova 4 | | SI-1000 Ljubljana | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | SDS Solvants, Documentation, Synthèses SA | | Z.I. de Valdonne, BP 4 | | F-13124 Peypin | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Sigma Aldrich Chemie GmbH | | Riedstraße 2 | | D-89555 Steinheim | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Sigma Aldrich Chimie SARL | | 80, rue de Luzais | | L'Isle-d'Abeau Chesne | | F-38297 Saint-Quentin-Fallavier | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | |  | | --- | | Sigma Aldrich Company Ltd | | The Old Brickyard | | New Road Gillingham SP8 4XT | | United Kingdom | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | Sigma Aldrich Laborchemikalien | | Wunstorfer Straße 40, Postfach 100262 | | D-30918 Seelze | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | VWR I.S.A.S. | | 201 rue Carnot | | F-94126 Fontenay-sous-Bois | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | |  | | --- | | YA-Kemia Oy — Sigma-Aldrich Finland | | Teerisuonkuja 4 | | FI-00700 Helsinki | |

Article 5

This Decision shall apply from 1 January 2005 and shall expire on 31 December 2005.

Done at Brussels, 23 August 2005.

For the Commission

Stavros DIMAS

Member of the Commission

---

---

ANNEX I

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Country | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol | Beclamethasone | Dexamethasone | Flunisolide | Fluticasone | Budesonide | Triamcinolone | Ipratropium bromide | Oxitropium bromide |
| Austria | Image 1 | Image 2 | Image 3 | Image 4 | Image 5 | Image 6 | Image 7 | Image 8 | Image 9 | Image 10 | Image 11 |  |  |  |  |  |  |  |  |
| Belgium | Image 12 | Image 13 | Image 14 | Image 15 | Image 16 | Image 17 | Image 18 | Image 19 | Image 20 | Image 21 | Image 22 |  |  |  |  |  |  |  |  |
| Cyprus | Image 23 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Czech Republic | Image 24 | Image 25 | Image 26 | Image 27 | Image 28 | Image 29 | Image 30 | Image 31 | Image 32 | Image 33 | Image 34 |  |  |  |  |  |  |  |  |
| Denmark | Image 35 |  | Image 36 | Image 37 | Image 38 | Image 39 | Image 40 | Image 41 | Image 42 | Image 43 | Image 44 |  |  |  |  |  |  |  |  |
| Estonia | Image 45 | Image 46 | Image 47 | Image 48 | Image 49 | Image 50 | Image 51 | Image 52 | Image 53 | Image 54 | Image 55 |  |  |  |  |  |  |  |  |
| Finland | Image 56 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| France | Image 57 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Germany | Image 58 | Image 59 | Image 60 | Image 61 | Image 62 | Image 63 | Image 64 | Image 65 | Image 66 | Image 67 | Image 68 | Image 69 | Image 70 | Image 71 | Image 72 | Image 73 | Image 74 | Image 75 | Image 76 |
| Greece | Image 77 | Image 78 | Image 79 | Image 80 | Image 81 | Image 82 | Image 83 | Image 84 | Image 85 | Image 86 | Image 87 |  |  |  |  |  |  |  |  |
| Hungary | Image 88 | Image 89 | Image 90 | Image 91 | Image 92 | Image 93 | Image 94 | Image 95 | Image 96 | Image 97 | Image 98 |  |  |  |  |  |  |  |  |
| Ireland | Image 99 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Latvia | Image 100 | Image 101 | Image 102 | Image 103 | Image 104 | Image 105 | Image 106 | Image 107 | Image 108 | Image 109 | Image 110 |  |  |  |  |  |  |  |  |
| Lithuania | Image 111 | Image 112 | Image 113 | Image 114 | Image 115 | Image 116 | Image 117 | Image 118 | Image 119 | Image 120 | Image 121 |  |  |  |  |  |  |  |  |
| Luxembourg | Image 122 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Poland | Image 123 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Portugal | Image 124 | Image 125 | Image 126 | Image 127 | Image 128 | Image 129 | Image 130 | Image 131 | Image 132 | Image 133 | Image 134 |  |  |  |  |  |  |  |  |
| The Netherlands | Image 135 | Image 136 | Image 137 | Image 138 | Image 139 | Image 140 | Image 141 | Image 142 | Image 143 | Image 144 | Image 145 |  |  |  |  |  |  |  |  |
| Norway | Image 146 | Image 147 | Image 148 | Image 149 | Image 150 | Image 151 | Image 152 | Image 153 | Image 154 | Image 155 | Image 156 |  |  |  |  |  |  |  |  |
| Slovak Republic | Image 157 | Image 158 | Image 159 | Image 160 | Image 161 | Image 162 | Image 163 | Image 164 | Image 165 | Image 166 | Image 167 |  |  |  |  |  |  |  |  |
| Slovenia | Image 168 | Image 169 | Image 170 | Image 171 | Image 172 | Image 173 | Image 174 | Image 175 | Image 176 | Image 177 | Image 178 |  |  |  |  |  |  |  |  |
| Spain | Image 179 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sweden | Image 180 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| UK | Image 181 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Source: www.unep.org/ozone/Information\_for\_the\_Parties/3Bi\_dec12-2-3.asp | | | | | | | | | | | | | | | | | | | |

---

ANNEX II

ESSENTIAL MEDICAL USES

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

|  |  |
| --- | --- |
|  | 3M Health Care (UK) |

|  |  |
| --- | --- |
|  | Aventis (UK) |

|  |  |
| --- | --- |
|  | Bespak (UK) |

|  |  |
| --- | --- |
|  | Boehringer Ingelheim (DE) |

|  |  |
| --- | --- |
|  | Chiesi (IT) |

|  |  |
| --- | --- |
|  | Glaxo Smith Kline (ES, FR, PL, UK) |

|  |  |
| --- | --- |
|  | IG Sprühtechnik (DE) |

|  |  |
| --- | --- |
|  | Inyx Pharmaceuticals (UK) |

|  |  |
| --- | --- |
|  | IVAX (IE) |

|  |  |
| --- | --- |
|  | Laboratorio Aldo-Unión (ES) |

|  |  |
| --- | --- |
|  | Sicor (IT) |

|  |  |
| --- | --- |
|  | V.A.R.I. (IT) |

|  |  |
| --- | --- |
|  | Valeas (IT) |

|  |  |
| --- | --- |
|  | Valois (FR) |

---

ANNEX III

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

|  |  |
| --- | --- |
|  | Agfa-Gevaert (BE) |

|  |  |
| --- | --- |
|  | Bie & Berntsen (DK) |

|  |  |
| --- | --- |
|  | Biosolve (NL) |

|  |  |
| --- | --- |
|  | Carl Roth (DE) |

|  |  |
| --- | --- |
|  | Elcom Group (CZ) |

|  |  |
| --- | --- |
|  | Honeywell Specialty Chemicals (DE) |

|  |  |
| --- | --- |
|  | Ineos Fluor (UK) |

|  |  |
| --- | --- |
|  | Katholieke Universiteit Leuven (BE) |

|  |  |
| --- | --- |
|  | LGC Promochem (DE) |

|  |  |
| --- | --- |
|  | Mallinckrodt Baker (NL) |

|  |  |
| --- | --- |
|  | Merck KGaA (DE) |

|  |  |
| --- | --- |
|  | Mikro + Polo (SI) |

|  |  |
| --- | --- |
|  | Panreac Química (ES) |

|  |  |
| --- | --- |
|  | SDS Solvants (FR) |

|  |  |
| --- | --- |
|  | Sanolabor (SI) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chemie (DE) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chimie (FR) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Company (UK) |

---

ANNEX IV

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

|  |  |
| --- | --- |
|  | Ineos Fluor (UK) |

|  |  |
| --- | --- |
|  | Ministry of Defense (NL) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chimie (FR) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Company (UK) |

---

ANNEX V

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

|  |  |
| --- | --- |
|  | Acros Organics (BE) |

|  |  |
| --- | --- |
|  | Agfa-Gevaert (BE) |

|  |  |
| --- | --- |
|  | Bie & Berntsen (DK) |

|  |  |
| --- | --- |
|  | Biosolve (NL) |

|  |  |
| --- | --- |
|  | Health Protection Inspectorate-Laboratories (EE) |

|  |  |
| --- | --- |
|  | Institut Scientifique de Service Public (ISSeP) (BE) |

|  |  |
| --- | --- |
|  | Katholieke Universiteit Leuven (BE) |

|  |  |
| --- | --- |
|  | Mallinckrodt Baker (NL) |

|  |  |
| --- | --- |
|  | Merck KGaA (DE) |

|  |  |
| --- | --- |
|  | Mikro + Polo (SI) |

|  |  |
| --- | --- |
|  | Panreac Química (ES) |

|  |  |
| --- | --- |
|  | Rohs Chemie (DE) |

|  |  |
| --- | --- |
|  | SDS Solvants (FR) |

|  |  |
| --- | --- |
|  | Sanolabor d.d. (SI) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chemie (DE) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chimie (FR) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Company (UK) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Laborchemikalien (DE) |

|  |  |
| --- | --- |
|  | VWR I.S.A.S. (FR) |

|  |  |
| --- | --- |
|  | YA-Kemia Oy (FI) |

---

ANNEX VI

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

|  |  |
| --- | --- |
|  | Acros Organics (BE) |

|  |  |
| --- | --- |
|  | Bie & Berntsen (DK) |

|  |  |
| --- | --- |
|  | Katholieke Universiteit Leuven (BE) |

|  |  |
| --- | --- |
|  | Mallinckrodt Baker (NL) |

|  |  |
| --- | --- |
|  | Merck KGaA (DE) |

|  |  |
| --- | --- |
|  | Mikro + Polo (SI) |

|  |  |
| --- | --- |
|  | Panreac Química (ES) |

|  |  |
| --- | --- |
|  | Sanolabor d.d. (SI) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chemie (DE) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chimie (FR) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Company (UK) |

|  |  |
| --- | --- |
|  | VWR I.S.A.S. (FR) |

|  |  |
| --- | --- |
|  | YA-Kemia Oy (FI) |

---

ANNEX VII

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

|  |  |
| --- | --- |
|  | Ineos Fluor (UK) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chimie (FR) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Company (UK) |

---

ANNEX VIII

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

|  |  |
| --- | --- |
|  | Ineos Fluor (UK) |

|  |  |
| --- | --- |
|  | Sigma Aldrich Chemie (DE) |

---

ANNEX IX

(This Annex is not published because it contains confidential commercial information.)

---

[Top](#document1)